Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis
Ankit Bharat1, Kishore Narayanan, Anjali Golocheikine
1Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
Insights
Hepatitis C virus recurrence post-transplant accelerates cirrhosis. A lack of Th1 immunity and elevated soluble CD30 (sCD30) indicate higher cirrhosis risk in liver transplant patients.
Area of Science:
- Immunology
- Hepatology
- Transplantation
Background:
- Hepatitis C virus (HCV) recurrence post-orthotopic liver transplantation (OLT) accelerates allograft cirrhosis.
- Current biochemical markers for monitoring HCV progression lack specificity and sensitivity.
Purpose of the Study:
- Investigate HCV-specific immunity (T-helper cell responses) and serum soluble CD30 (sCD30) levels.
- Determine association between immune profiles, sCD30, and allograft cirrhosis in OLT recipients.
Main Methods:
- Compared HCV-specific CD4 T(h1) (IFN-gamma) and T(h2) (IL-5) cell frequencies in patients with and without allograft cirrhosis.
- Measured serum levels of soluble CD30 (sCD30) in both patient groups.
Main Results:
- Patients with hepatic inflammation but no cirrhosis (HIN) showed higher interferon (IFN)-gamma and T(h1) cells.
- Patients with hepatic cirrhosis (HFC) exhibited higher interleukin (IL)-5 and T(h2) cells.
- Significantly elevated sCD30 levels were observed in HFC patients compared to HIN patients.
Conclusions:
- A deficiency in Th1-type CD4 T cell responses is linked to HCV-induced allograft cirrhosis.
- Serum sCD30 may serve as a novel biomarker for monitoring hepatic cirrhosis in HCV-infected liver transplant recipients.
Abstract:
Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) significantly accelerates progression to allograft cirrhosis. Current biochemical parameters to monitor progression of chronic HCV after OLT have yielded low specificity and sensitivity. Here we investigated the HCV-specific immunity and serum levels of soluble CD30 (sCD30), a novel marker of Th2 immunity, in patients with and without allograft cirrhosis. Patients with hepatic inflammation but no cirrhosis (HIN, n=20) revealed elevated serum interferon (IFN)-gamma and high frequency of IFN-gamma producing CD4 T(h1) cells compared to those with hepatic cirrhosis (HFC, n=20) that had high interleukin (IL)-5 and IL-5 producing CD4 T(h2) cells. Patients with HFC, but not HIN, were found to have significantly higher levels of sCD30. Therefore, we conclude that lack of optimal Th1-type CD4 T cells is associated with HCV-induced allograft cirrhosis. Further, sCD30 may represent a novel marker for surveillance of hepatic cirrhosis in transplant recipients with chronic HCV infection.
Related Concept Videos
Hepatitis
Cirrhosis I: Introduction
Cirrhosis II: Pathophysiology

